NCT05494580View on ClinicalTrials.gov

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

September 22, 2022

Primary Completion Date

August 10, 2024

Study Completion Date

August 10, 2025

Conditions

Ovarian CancerOvarian CarcinomaPlatinum-resistant Ovarian CancerFallopian Tube CarcinosarcomaPrimary Peritoneal Cancer

Interventions

DRUG

Pamiparib

Oral

DRUG

Surufatinib

Oral

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Cetntre, Guangzhou

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Hutchmed

INDUSTRY

lead

Sun Yat-sen University

OTHER